source
- Expert discusses how clinicians choose between FOLFIRINOX and newly approved NALIRIFOX for metastatic pancreatic cancerDr. Deirdre J. Cohen, director of GI Oncology at Mount Sinai, provides commentary on how doctors decide on frontline chemotherapy for metastatic pancreatic cancer. She notes that, as of 2026, ther…
- Phase 1 trial of HS-10504 shows encouraging responses in EGFR C797S mutant lung cancerHS-10504, an investigational therapy, was evaluated in a Phase 1 study in patients with non-small cell lung cancer harboring the EGFR C797S mutation after progression on prior tyrosine kinase inhib…